Informações:
Falhas:
ID
19592
Descrição
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00371345
Link
https://clinicaltrials.gov/show/NCT00371345
Palavras-chave
Versões (1)
- 13/01/2017 13/01/2017 -
Transferido a
13 de janeiro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00371345
Eligibility Breast Cancer NCT00371345
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00371345
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Gender | Age
Item
females, 18 or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Breast cancer recurrent | Locally advanced breast cancer | Secondary malignant neoplasm of female breast | Estrogen Receptor expression | Progesterone Receptor expression | ERBB2 Protein Overexpression
Item
recurrent, locally advanced, or metastatic breast cancer with expression of er/pr receptor and/or overexpression of her2/neu
boolean
C0278493 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
C0034804 (UMLS CUI [4,1])
C1171362 (UMLS CUI [4,2])
C0034833 (UMLS CUI [5,1])
C1171362 (UMLS CUI [5,2])
C1515560 (UMLS CUI [6])
C3495949 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
C0034804 (UMLS CUI [4,1])
C1171362 (UMLS CUI [4,2])
C0034833 (UMLS CUI [5,1])
C1171362 (UMLS CUI [5,2])
C1515560 (UMLS CUI [6])
Paraffin Embedded Tissue Available
Item
paraffin-embedded tissue block must be available
boolean
C1519524 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,2])
Measurable Disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Neoplasm Metastasis | Anthracycline | taxane
Item
prior chemotherapy with an anthracycline and/or a taxane (neoadjuvant, adjuvant, or metastatic setting)
boolean
C0600558 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0085533 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C0027627 (UMLS CUI [3,2])
C0282564 (UMLS CUI [4])
C0215136 (UMLS CUI [5])
C0392920 (UMLS CUI [1,2])
C0085533 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C0027627 (UMLS CUI [3,2])
C0282564 (UMLS CUI [4])
C0215136 (UMLS CUI [5])
Chemotherapy Quantity Neoplasm Metastasis
Item
0, 1 or 2 chemotherapies in the metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
organ function
Item
adequate organ function
boolean
C0678852 (UMLS CUI [1])
Secondary malignant neoplasm of bone
Item
metastatic disease confined to bone only
boolean
C0153690 (UMLS CUI [1])
CNS metastases Symptomatic
Item
symptomatic central nervous system (cns) metastasis
boolean
C0686377 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
Toxicity Risk Increased
Item
concurrent medical condition which may increase the risk of toxicity
boolean
C0600688 (UMLS CUI [1,1])
C0035647 (UMLS CUI [1,2])
C0442805 (UMLS CUI [1,3])
C0035647 (UMLS CUI [1,2])
C0442805 (UMLS CUI [1,3])
Oral medication administration Unable
Item
unable to take oral medication
boolean
C0001563 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,2])